Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

BIOALLIANCE PHARMA SA (C4X)
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 4,90 M
EBIT 2017 -24,0 M
Net income 2017 -24,0 M
Finance 2017 17,0 M
Yield 2017 -
Sales 2018 30,0 M
EBIT 2018 -10,0 M
Net income 2018 -10,0 M
Finance 2018 6,00 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 12,2x
EV / Sales2018 2,35x
Capitalization 76,5 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : - Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
10/17 Onxeo Reports First Instance Decision from the Commercial Court of Paris in t..
10/02 Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oli..
09/28 ONXEO : Patent Issued for Nanoparticles Loaded with Chemotherapeutic Antitumoral..
09/28 ONXEO : announces compelling preclinical data in combination for its two innovat..
09/28 Onxeo announces compelling preclinical data in combination for its two innov..
09/14 ONXEO : Grants Exclusive Worldwide License of Validive Developed for the Treatme..
09/14 ONXEO : Phase 3 hepatocellular carcinoma fail crushes Onxeo
09/13 Onxeo Grants Exclusive Worldwide License of Validive® Developed for the Treat..
09/11 Onxeo Announces Top-Line Results from ReLive Phase III Study of Livatag® in A..
07/05 Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiD..
More news
Sector news : Pharmaceuticals - NEC
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus UNDERPERFORM
Number of Analysts 1
Average target price 1,40 €
Spread / Average Target -7,3%
EPS Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Françoise Bono Chief Scientific Officer
Olivier de Beaumont Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA90
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223